Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates

Article Medicine, Research & Experimental

Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters

Srinivasu Poondru et al.

Summary: This study evaluated the effect of enzalutamide on the pharmacokinetics of digoxin and rosuvastatin in men with metastatic castration-resistant prostate cancer. The results showed a mild inhibitory effect of enzalutamide on P-gp, but no interaction with BCRP. The risk of transporter-mediated drug-drug interaction between enzalutamide and digoxin/rosuvastatin is low in prostate cancer patients, and dose adjustment is not necessary.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)

Add to Collection

Article Hematology

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

Gary H. Lyman et al.

Summary: These evidence-based guidelines aim to support decision-making on the prevention and treatment of VTE in cancer patients, covering mechanical and pharmacological prophylaxis, as well as recommendations for initial, short-term, and long-term treatment based on patient risk and treatment circumstances. Recommendations vary depending on patient risk level and treatment situation.

BLOOD ADVANCES (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption

Wen Kou et al.

Summary: In the metabolism of rivaroxaban, the involvement of intestinal efflux transporters has little clinical significance, with drug interactions most likely predicted based on CYP metabolism levels.

PHARMACEUTICAL RESEARCH (2021)

Add to Collection

Article Critical Care Medicine

Antithrombotic Therapy for VTE Disease Second Update of the CHEST Guideline and Expert Panel Report

Scott M. Stevens et al.

Summary: This is the 2nd update to the 9th edition of guidelines, providing recommendations on 17 PICO questions, with four new questions addressed. Strong and weak recommendations were generated based on high-, moderate-, and low-certainty evidence, resulting in 29 guidance statements, 13 of which are strong recommendations. New evidence has emerged since 2016, improving the standard of care for VTE patients, but substantial uncertainty remains regarding certain important management questions.

CHEST (2021)

Add to Collection

Article Chemistry, Multidisciplinary